Compare · BSX vs DRIO
BSX vs DRIO
Side-by-side comparison of Boston Scientific Corporation (BSX) and DarioHealth Corp. (DRIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and DRIO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.32B, about 1166.8x DRIO ($53.4M).
- Over the past year, BSX is down 54.6% and DRIO is down 62.6% - BSX leads by 8.0 points.
- DRIO has been more active in the news (10 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 5 for DRIO).
- Company
- Boston Scientific Corporation
- DarioHealth Corp.
- Price
- $44.38+0.50%
- $5.00-5.12%
- Market cap
- $62.32B
- $53.4M
- 1M return
- +1.88%
- -27.64%
- 1Y return
- -54.61%
- -62.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 10
- Recent ratings
- 25
- 5
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest DRIO
- DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
- Director Shaked Yoav converted options into 772 shares and was granted 54,000 shares, increasing direct ownership by 167% to 87,582 units (SEC Form 4)
- Director Mcgrath Dennis M was granted 61,000 shares, increasing direct ownership by 220% to 88,737 units (SEC Form 4)
- Director Palumbo John R was granted 62,000 shares, increasing direct ownership by 1,378% to 66,500 units (SEC Form 4)
- Director Stern Adam K converted options into 20,195 shares and was granted 28,000 shares, increasing direct ownership by 94% to 57,717 units (SEC Form 4)
- Director Matheis Dennis was granted 44,000 shares, increasing direct ownership by 102% to 87,026 units (SEC Form 4)
- Chief Financial Officer Franco-Yehuda Chen was granted 95,000 shares, increasing direct ownership by 317% to 125,000 units (SEC Form 4)
- Director Karah Hila was granted 28,000 shares, increasing direct ownership by 90% to 58,965 units (SEC Form 4)
- Chief Executive Officer Raphael Erez converted options into 579 shares and was granted 297,000 shares, increasing direct ownership by 190% to 454,432 units (SEC Form 4)
- New insider Sherman Lara Ann claimed ownership of 120,000 shares (SEC Form 3)